BioCentury
ARTICLE | Finance

Companies dust off alternative funding tools in bear market

A persistent market downturn is driving cash-strapped public biotechs to reach for financing tools little used in recent years

March 18, 2022 7:58 PM UTC

With follow-on financing activity falling off a cliff, public companies in need of fresh capital will have to dust off the financial toolbox of past downturns and start weighing alternative financing options that could work for them should the public markets remain largely closed this year. 

The lack of activity so far in 2022 is partly due to company reticence to finance at low valuations, and partly to investors being more discerning in their search for out-performance. ...